Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36. doi: 10.1016/j.jchromb.2003.10.025.

Abstract

An isocratic online-enrichment HPLC-assay was developed allowing for the simple and fast separation and quantitation of STI-571 and its main metabolite N-desmethyl-STI (N-DesM-STI) in plasma, urine, cerebrospinal fluid (CSF), culture media and cell preparations in various concentrations using UV-detection at 260 nm. The analytical procedure consists of an online concentration of STI-571 and N-DesM-STI in the HPLC system followed by the elution on a ZirChrom-PBD analytical column. Time of analysis is 40 min including the enrichment time of 5 min. The detection limit is 10 ng/ml in plasma, CSF, culture medium (RPMI) and 25 ng/ml in urine for both STI-571 and N-DesM-STI. The intra-day precision, as expressed by the coefficient of variation (CV), in plasma samples ranges between 1.74 and 8.60% for STI-571 and 1.45 and 8.87% for N-DesM-STI. The corresponding values for urine measurements are 2.17-7.54% (STI-571) and 1.31-9.51% (N-DesM-STI). The inter-day precision analyzed over a 7-month time period was 8.31% (STI-571) or 6.88% (N-DesM-STI) and 16.45% (STI-571) or 14.83% (N-DesM-STI) for a concentration of 1000 ng/ml in plasma and 750 ng/ml in urine, respectively. Moreover, we demonstrate that with an alternative, but more time and labor consuming sample preparation and the implementation of electrochemical detection, a detection limit < 10 ng/ml can be achieved. The method described was used to perform pharmacokinetic measurements of STI-571 and N-desmethyl-STI in patient samples and for kinetic measurements of intracellular STI-571 and N-DesM-STI following in vitro incubation.

MeSH terms

  • Antineoplastic Agents / blood
  • Antineoplastic Agents / cerebrospinal fluid
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / urine
  • Benzamides
  • Chromatography, High Pressure Liquid / methods*
  • Culture Media
  • Electrochemistry
  • Enzyme Inhibitors / blood
  • Enzyme Inhibitors / cerebrospinal fluid
  • Enzyme Inhibitors / pharmacokinetics*
  • Enzyme Inhibitors / urine
  • HL-60 Cells
  • Humans
  • Imatinib Mesylate
  • Piperazines / blood
  • Piperazines / cerebrospinal fluid
  • Piperazines / pharmacokinetics*
  • Piperazines / urine
  • Pyrimidines / blood
  • Pyrimidines / cerebrospinal fluid
  • Pyrimidines / pharmacokinetics*
  • Pyrimidines / urine
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectrophotometry, Ultraviolet

Substances

  • Antineoplastic Agents
  • Benzamides
  • Culture Media
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate